BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire  ¹     Toshifumi Hibi  ²     Alessandra Oortwijn  ³     Simon Hatch  ⁴     Silvio Danese  ⁵     Brian G. Feagan  ⁶     William Sandborn  ^7    
1 Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
² Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan
³ Galapagos NV, Leiden, Netherlands
⁴ Galapagos Inc., Waltham, MA, United States
⁵ IBD Center, Humanitas Research Hospital, Milan, Italy
⁶ Robarts Research Institute, Western University, London, ON, Canada
⁷ University of California San Diego, La Jolla, CA, United States

Session
IBD: Clinical trials poster II

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)